AMP423

AMP423 is a novel cyanoaziridine derivative and a naphthyl analog of 2-cyanoaziridine-1-carboxamide, developed by Amplimed Corporation. Structurally similar to the iminopyrrolidone-based pro-oxidant anti-tumor agent imexon, AMP423 is more lipophilic and exhibits significantly greater cytotoxic potency across various cancer types, including multiple myeloma, pancreatic, and colorectal cancers. Its mechanism of action involves the induction of oxidative stress, characterized by the generation of reactive oxygen species (ROS), depletion of cellular thiols, and loss of mitochondrial membrane potential, ultimately leading to S-phase cell cycle arrest and apoptosis via caspase-3 activation. Unlike other aziridine-containing compounds, AMP423 does not appear to act as a traditional alkylating agent, likely due to the presence of a cyano group that reduces reactivity toward cellular nucleophiles. Preclinical studies have demonstrated its efficacy as a single agent in lymphoma and myeloma xenografts, and in combination with gemcitabine for pancreatic cancer.

Other names

naphthyl derivative of 2-cyanoaziridine-1-carboxamide